CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenue:
Genetic testing	$ 731,194	$ 531,151	$ 2,229,757	$ 1,460,601
Other	34,222	13,593	52,008	25,805
Total revenue	765,416	544,744	2,281,765	1,486,406
Cost of revenue	370,740	409,010	1,166,793	1,254,033
Gross profit	394,676	135,734	1,114,972	232,373
Operating expenses:
Research and development	324,669	317,155	989,287	1,059,450
Selling, general and administrative	1,086,606	1,168,314	3,542,203	4,209,879
Amortization of intangibles	28,863	28,863	86,590	86,590
Total operating expenses	1,440,138	1,514,332	4,618,080	5,355,919
Loss from operations	(1,045,462)	(1,378,598)	(3,503,108)	(5,123,546)
Other income (expense):
Interest income	1,030	1,522	5,337	2,724
Interest expense	(90,110)	(73,726)	(267,390)	(213,254)
Gain on disposal of assets		8,659	4,275	33,159
Total other expense	(89,080)	(63,545)	(257,778)	(177,371)
Loss from continuing operations before income taxes	(1,134,542)	(1,442,143)	(3,760,886)	(5,300,917)
Benefit for income taxes
Loss from continuing operations	(1,134,542)	(1,442,143)	(3,760,886)	(5,300,917)
Income from discontinued operations, net of income taxes			158,366	482,530
Net loss	$ (1,134,542)	$ (1,442,143)	$ (3,602,520)	$ (4,818,387)
Basic and diluted net loss per common share from:
Continuing operations	$ (0.03)	$ (0.04)	$ (0.10)	$ (0.15)
Discontinued operations			$ 0.00	$ 0.01
Net Loss	$ (0.03)	$ (0.04)	$ (0.10)	$ (0.14)
Weighted average common shares outstanding, basic and diluted	36,674,829	36,545,747	36,647,874	35,410,705